 |
Mereo acquired a portfolio of three product candidates from Novartis in July 2015 including setrusumab (BPS-804), acumapimod (BCT-197), and leflutrozole (BGS-649). |
 |
Mereo in-licensed alvelestat (MPH-966) from AstraZeneca in October 2017. |
  |
Mereo out-licensed navicixizumab (OMP-305B83) to OncXerna Therapeutics, Inc. in January 2020. |
 |
Mereo entered a collaboration and license agreement with Ultragenyx Pharmaceutical, Inc. for the development and co-commercialisation of setrusumab (BPS-804) in December 2020. |
